Vanda Pharmaceuticals Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VNDA research report →
Companywww.vandapharma.com
Vanda Pharmaceuticals Inc. , a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
- CEO
- Mihael H. Polymeropoulos
- IPO
- 2006
- Employees
- 368
- HQ
- Washington, DC, US
Price Chart
Valuation
- Market Cap
- $371.94M
- P/E
- -1.54
- P/S
- 1.71
- P/B
- 1.31
- EV/EBITDA
- -2.31
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 92.46%
- Op Margin
- -73.64%
- Net Margin
- -109.99%
- ROE
- -61.41%
- ROIC
- -52.76%
Growth & Income
- Revenue
- $216.10M · 8.72%
- Net Income
- $-220,474,000 · -1066.53%
- EPS
- $-3.74 · -1068.75%
- Op Income
- $-151,168,000
- FCF YoY
- -579.76%
Performance & Tape
- 52W High
- $9.94
- 52W Low
- $4.14
- 50D MA
- $7.23
- 200D MA
- $6.22
- Beta
- 0.65
- Avg Volume
- 2.45M
Get TickerSpark's AI analysis on VNDA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 22, 26 | Duncan Charles Cliff | other | 57,101 |
| Apr 22, 26 | Duncan Charles Cliff | other | 0 |
| Apr 1, 26 | Polymeropoulos Christos Vasilios Mihael | other | 0 |
| Apr 1, 26 | Polymeropoulos Christos Vasilios Mihael | other | 0 |
| Apr 1, 26 | Polymeropoulos Christos Vasilios Mihael | other | 0 |
| Apr 1, 26 | Polymeropoulos Christos Vasilios Mihael | other | 0 |
| Apr 1, 26 | Polymeropoulos Christos Vasilios Mihael | other | 0 |
| Apr 1, 26 | Polymeropoulos Christos Vasilios Mihael | other | 61,200 |
| Apr 1, 26 | Howell Scott Laverne | other | 0 |
| Apr 1, 26 | Howell Scott Laverne | other | 0 |
Our VNDA Coverage
We haven't published any research on VNDA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VNDA Report →